AbbVie to bolster immunity illness drug pipeline with Landos deal
Reuters
Published Mar 25, 2024 08:39AM ET
Updated Mar 25, 2024 11:21AM ET
(Reuters) -AbbVie will buy drug developer Landos Biopharma for up to $212 million as the Humira-maker aims to expand its pipeline of medicines to treat immune system-related illnesses, the companies said on Monday.
Landos is currently conducting a mid-stage study of its lead experimental drug NX-13 in a type of an inflammatory bowel disease called ulcerative colitis.
AbbVie (NYSE:ABBV)'s blockbuster drug Rinvoq is approved to treat the disease while the company has also sought the U.S. Food and Drug Administration's approval for its other key drug Skyrizi.
Under the deal, AbbVie will buy Landos for $20.42 per share in cash, or about $137.5 million in total. The offer marks a 161% premium to Friday's close of $7.83.
Landos' shares surged to $22.13 before the bell after a short trading halt.
AbbVie has also agreed to pay Landos shareholders an additional up to $11.14 per share, or around $75 million in total, contingent on certain clinical development milestones.
The deal is expected to close in the second quarter, the companies said.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.